1Pentikainen JP, Saraheimo M, Schwartz JI, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol, 1992, 32:136
2Davidson MH, Stein EA, Dujovre CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. American J of Cardiol, 1997, 79(Jan):38
3Stubbs RJ, Schwartz MS, Gerson RJ, et al. Comparison of plasma profiles lovastatin (mevinolin), simvastatin (epistatin) and pravastatin (eptastatin) in the dog. Drug Invest, 1990, 2:18
4.SummaryofthesecondreportoftheNationalCholesterolEducationProgram (NCEP)ExpertPanelondetection ,evaluationandtreat mentofhighbloodcholesterolinadults (AdultTreatmentPanel11)[].The Journal of The American Medical Association.1993
7Farmer JA,Gotto AM.Dyslipidemia and other risk factors for coronary artery disease.In Braunwald E ed: Heart disease: a textbook of cardiovasular medicine, 5th Ed. 1997, W. B. Saunders Co[].Philadelphia Medicine.
8Bischoff H. Angerbauer R,Bender J,et al.Cerivastatin: pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor[].Atherosclerosis.1997
9Bakker-Arkema RG,Davidson MH,Goldstern RJ,et al.Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[].The Journal of The American Medical Association.1996
10Bocuzzi SJ,Bocanegra TS,Walker JF,et al.Long-tem safety and efficacy profile of simvastatin[].The American Journal of Cardiology.1991
